Estrogen Therapy and Blood Clots: What You NEED To Know

Estrogen therapy can increase blood clot risk — but the degree of risk depends heavily on how the estrogen is delivered. Oral estrogen, which is metabolized by the liver before entering systemic circulation, triggers the liver to produce increased levels of clotting factors including Factor VIII and fibrinogen, raising the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). Transdermal and sublingual estradiol bypass the liver entirely, entering the bloodstream directly without triggering this hepatic clotting factor response. Research consistently shows that transdermal estradiol does not significantly elevate clotting risk above baseline — a distinction that is clinically meaningful and often underemphasized when women are counseled about HRT safety.

The difference is first-pass hepatic metabolism. When estrogen is taken orally, it is absorbed through the gastrointestinal tract and travels directly to the liver before reaching systemic circulation. This liver exposure stimulates the hepatic production of several clotting factors — proteins that increase the blood’s tendency to form clots. The more potent the estrogen and the higher the dose, the greater this effect. Transdermal estrogen — applied as a patch, gel, cream, or spray — absorbs through the skin directly into the bloodstream, bypassing the liver entirely. Sublingual estradiol absorbs under the tongue into the sublingual blood vessels, similarly avoiding first-pass liver metabolism. Without the liver activation step, the clotting cascade is not stimulated and thrombotic risk does not increase in the same way.

Oral estrogen approximately doubles the baseline risk of venous thromboembolism (VTE) — meaning deep vein thrombosis or pulmonary embolism — compared to non-users. In absolute terms, the baseline risk of VTE in healthy postmenopausal women is low, so doubling a small risk still represents a relatively small absolute increase. However, for women with additional risk factors — clotting disorders, obesity, smoking, prolonged immobility, or family history of DVT — the relative risk increase from oral estrogen compounds significantly. By contrast, multiple large studies have found that transdermal estradiol produces no statistically significant increase in VTE risk compared to non-users, making delivery method the most important modifiable variable in the HRT-clotting risk equation.

Several factors substantially elevate the clotting risk associated with estrogen therapy and warrant careful evaluation before initiating any hormonal treatment. A personal history of deep vein thrombosis or pulmonary embolism is the most significant risk factor. Inherited thrombophilias — particularly Factor V Leiden mutation, which impairs the body’s ability to regulate clot formation — significantly amplify estrogen-related risk and should be tested for in women with a personal or family history of clotting events. Obesity increases baseline clotting risk independently and compounds the effect of oral estrogen. Smoking damages vascular endothelium and promotes clot formation. Prolonged immobility — including long-haul travel or post-surgical recovery — creates temporary windows of elevated risk. Women with any of these factors should discuss their specific risk profile with a healthcare provider before beginning HRT, and transdermal delivery should be strongly preferred over oral if HRT is appropriate.

No — and this distinction is critical. The Women’s Health Initiative (WHI) study that raised widespread concerns about HRT safety used oral conjugated equine estrogen — not bioidentical transdermal estradiol. The elevated clotting risk documented in that study was a finding specific to oral synthetic estrogen and cannot be generalized to transdermal bioidentical estradiol. Subsequent research has consistently shown that transdermal estradiol does not carry the same thrombotic risk as oral estrogen, and that bioidentical progesterone does not carry the additional clotting and cardiovascular risk signals associated with synthetic progestins. The conflation of these very different hormone types and delivery methods in public and clinical discourse has led to unnecessary avoidance of HRT options that carry a significantly more favorable safety profile.